Tamoxifen And Breast Cancer
Download Tamoxifen And Breast Cancer full books in PDF, epub, and Kindle. Read online free Tamoxifen And Breast Cancer ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author | : Michael W. DeGregorio |
Publisher | : Yale University Press |
Total Pages | : 132 |
Release | : 1999-01-01 |
Genre | : Medical |
ISBN | : 9780300079517 |
A discussion of the diagnosis of breast cancer and the risks, benefits and limitations of treatment alternatives, particularly tamoxifen. This edition contains information on developments in the use of tamoxifen, especially in the results of the Breast Cancer Prevention Trial.
Author | : Virgil Craig Jordan |
Publisher | : Oncology Group |
Total Pages | : 309 |
Release | : 1999-01-01 |
Genre | : Breast |
ISBN | : 9781891483004 |
Intended for the physician whose primary discipline is not medical oncology, but whose practice includes women at risk for breast cancer and/or women who are either taking tamoxifen to treat breast cancer, or women who are taking raloxifene to prevent osteoporosis. Also recommended for nurses in breast care centers who are responsible for the day-to-day care of women.
Author | : K. I. Bland |
Publisher | : Saunders |
Total Pages | : 822 |
Release | : 2009 |
Genre | : Medical |
ISBN | : |
Offering the most comprehensive, up-to-date information on the diagnosis and management of, and rehabilitation following, surgery for benign and malignant diseases of the breast, this surgical reference is now in a new edition available in both print and online for easy, convenient access to the absolute latest advances.
Author | : Kim Horner |
Publisher | : University of North Texas Press |
Total Pages | : 209 |
Release | : 2019-02-15 |
Genre | : Biography & Autobiography |
ISBN | : 1574417576 |
After learning that she inherited a BRCA2 genetic mutation that put her at high risk for breast and ovarian cancer, Kim Horner’s doctors urged her to consider having a double mastectomy. But how do you decide whether to have a surgery to remove your breasts to reduce your risk for a disease you don’t have and may never get? Horner shares her struggle to answer that question in Probably Someday Cancer. The mother of a one-year-old boy, she wanted to do whatever would give her the best odds of being around for her son and protect her from breast cancer, which killed her grandmother and great-grandmother in their 40s. Which would give her the best chance at a long healthy life: a double mastectomy or frequent screenings to try to catch any cancer early? The answers weren’t that simple. Based on extensive research, interviews, and personal experience, Horner writes about how and why she ultimately opted for a double mastectomy—the same decision actress Angelina Jolie made for a similar genetic mutation—and the surprising diagnosis that followed. The book explores difficult truths that get overshadowed by upbeat messages about early detection and survivorship—the fact that screenings can miss cancers and that even early-stage breast cancers can spread and become fatal. Probably Someday Cancer is about the author’s efforts to push past her fear and anxiety. This book can help anyone facing hereditary risk of breast and ovarian cancer feel less alone and make informed decisions to protect their health and end the devastation that hereditary cancer has caused for generations in so many families.
Author | : Philipp Y. Maximov |
Publisher | : Springer Science & Business Media |
Total Pages | : 218 |
Release | : 2013-07-23 |
Genre | : Medical |
ISBN | : 3034806647 |
Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.
Author | : Rogerio A. Lobo |
Publisher | : Elsevier |
Total Pages | : 902 |
Release | : 2007-06-05 |
Genre | : Technology & Engineering |
ISBN | : 0080553095 |
For anyone who treats postmenopausal women, this latest edition of Rogerio Lobo's classic work combines the best from two well-known references: Menopause, and the second edition of Treatment of the Postmenopausal Woman. By adding significant discussions of the basic science behind menopause, it is possible to objectively assess the clinical value and limitations of current approaches to treatment and provide a basis and rationale for strategies that will result in better individualized and specialized care. Not only does the third edition discuss diagnosis and treatment of menopause but it covers biological, anatomical, physiological, pathobiological, and pharmacological aspects as well bringing together, in one source, all of the information needed to understand and treat postmenopausal conditions. Over 50% new material representing the vast amount of information available since the Women's Health Initiative (WHI) clinical trials were completed making this the most up-to-date reference on postmenopausal women Includes several new sections on comparisons between clinical trials and observational data, urology, and pelvic support Each section is preceded by a preface to put the area into context with many chapters having suggested treatment regimens
Author | : Virgil Craig Jordan |
Publisher | : Univ of Wisconsin Press |
Total Pages | : 320 |
Release | : 1994 |
Genre | : Health & Fitness |
ISBN | : 9780299140700 |
During the past twenty years tamoxifen has become the most widely prescribed and most successful drug used in the treatment of breast cancer. In this volume, editor V. Craig Jordan provides articles that trace the development, pharmacology, and clinical research surrounding this drug which, by the year 2000, could be used to treat as many as one million women annually. Drawing from research conducted by specialists in the United States, the United Kingdom, and Italy, the series of articles describes the clinical testing of tamoxifen, highlighting the benefits. Studies show that tamoxifen lowers cholesterol and can potentially protect women against osteoporosis and fatal coronary heart disease. Equally important is a discussion of side effects and possible drug interactions and how these issues relate to patient concerns. An investigation of the development of a new class of drugs for use after tamoxifen fails provides valuable insight into future treatments, as the contributers consider possible resistance to tamoxifen. This volume provides invaluable information for physicians and surgeons who care for patients with breast cancer and for women interested in exploring this therapeutic dimension.
Author | : Gw Sledge |
Publisher | : Clinical Pub |
Total Pages | : 0 |
Release | : 2012-06 |
Genre | : Breast |
ISBN | : 9781846920660 |
This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
Author | : Monica Castiglione |
Publisher | : Springer Science & Business Media |
Total Pages | : 483 |
Release | : 2009-07-11 |
Genre | : Medical |
ISBN | : 0387751157 |
Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.
Author | : John A. Kellen |
Publisher | : Springer Science & Business Media |
Total Pages | : 383 |
Release | : 2012-12-06 |
Genre | : Medical |
ISBN | : 1461240921 |
Tamoxifen has persisted as a widely accepted and administered drug for almost 25 years. Following the many scientific papers and books on the subject, it has remained a very intriguing substance. This, perhaps, is the reason for another monograph on Tamoxifen. It is regrettably true that overviews, even when up to date after exhaustive research - the shibboleth of our cultures -, rapidly lose relevance with the passage of time. Scientists can sometimes be pictured as deep sea divers, who plunge into the unknown in search of a hitherto unknown world. Their descent is exciting, but eventually they must come up for air and integrate their experiences with others who also had to resurface. This book intends to collect and, where possible, to collate recent, but sometimes seemingly unrelated information. To quote Stephane Mallarme: "Everything in the world exists to end up in a book". Even if this is a tad cynical, it might not be far from the truth. If a little knowledge is a dangerous commodity, one can also add - tongue in cheek - that a vast amount of knowledge can be truly hazardous. It is likely that what might seem as entangled data is confusing, especially for those satisfied with the comfortable interpretation of Tamoxifen as an antiestrogen which has long been found insufficient. The complexity of its mechanisms and effects defies simple explanations and may even seem capricious, but only because of our ignorance.